Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

t-experienced patients with HCV genotype 1. In this study, low doses of ritonavir were used for metabolic inhibition to enhance the levels of SCH 900518 within the body and reduce the frequency of SCH 900518 dosing (BID vs. TID).

In the study, SCH 900518 administered as monotherapy exhibited potent antiviral activity, achieving 4.0-4.5 log10 decreases in viral load (HCV RNA) from baseline at day 8. SCH 900518 was well tolerated, with no drug related serious adverse events. Pharmacokinetic and pharmacodynamic modeling from this study was used to design the ongoing Phase IIa dose-finding study of SCH 900518 with ritonavir in combination with PEGINTRON and REBETOL. This study, known as NEXT-1, explores SCH 900518 in 200 mg, 400 mg or 600 mg once daily (QD) doses with low-dose ritonavir (100 mg) in combination with PEGINTRON and REBETOL (with and without a 4-week P/R lead-in period) in treatment-naive patients with HCV genotype 1.

About the HCV SPRINT-1 Study

In this Phase II study, known as HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated in three treatment regimens: 4 weeks of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) therapy followed by the addition of boceprevir to the combination for 24 or 44 weeks (totaling 28 or 48 weeks of treatment), boceprevir in combination with PEGINTRON and REBETOL at the doses described above for 28 or 48 weeks, and, in Part II of the study, boceprevir in combination with PEGINTRON and low-dose REBETOL (400-1000 mg daily based on patient weight) for 48 weeks. In Part I of the study, the boceprevir regimens were compared to a control of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) alone for 48 weeks (an approved treatment regimen). In Part II of the study, boceprevir in combination with PEGINTRON and low-dose REBETOL for 48 weeks was compared t
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... LAKE CITY , Sept. 15, 2014 /PRNewswire/ ... solutions to the medical device market, announced its ... of Biomerics Advanced Catheter Division. The new division was ... invasive surgical device solutions for the structure heart, ... Biomerics Advanced Catheter will be ...
(Date:9/15/2014)... 2014 Chek Diagnostics, the U.S.-based manufacturer of ... point-of-care diagnostic products, has again been named to the ... companies in America. The Inc. 5000 ranking ... Chek Diagnostics earned its place on the list by ... 2013. For Chek Diagnostics, who appears on ...
(Date:9/15/2014)...  The Female Health Company (NASDAQ-CM: FHCO) today announced ... management team as Executive Vice President of Global Operations ... Michael Pope will retire from his position ... 15, 2014.  Following his retirement, Mr. Pope will continue ... Prior to joining The Female Health Company (FHC), ...
Breaking Medicine Technology:Biomerics and Access Point Technologies OEM Announce Merger and Creation of Biomerics Advanced Catheter Division 2Chek Diagnostics Named to Inc. Magazine's 5000 Fastest Growing Private Companies List for the Fourth Time 2Chek Diagnostics Named to Inc. Magazine's 5000 Fastest Growing Private Companies List for the Fourth Time 3The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations 2The Female Health Company Appoints Martin Tayler Executive Vice President of Global Operations 3
(Date:9/15/2014)... September 15, 2014 Ondine Biomedical ... Loebel, its President and Chief Technology Officer, will ... Photodynamic Therapy (PDT) and Photodiagnosis in Clinical Practice. ... Brixen/Bressanone (Italy) from October 14-18, 2014 alongside the ... on October 13-14th, is an annual conference at ...
(Date:9/15/2014)... Octo Consulting Group, a leading provider ... federal government, today announced it is opening two ... to better serve existing and future federal government ... to the strong growth momentum of the company’s ... consulting, agile software development, data visualization, and data ...
(Date:9/15/2014)... approximately one out of every 40 individuals in the United ... muscular atrophy (SMA), a neurodegenerative disease that causes muscles to ... have made a recent breakthrough with the development of a ... of the disease. In April, a patent was filed for ... lab is using to fight SMA is to ,repress the ...
(Date:9/15/2014)... Ohio (PRWEB) September 15, 2014 In ... math and medicine often act conjointly to quantify, define ... industry has become an integral part of medical care. ... regularly reports the studies conducted by the non-profit Institute ... have consistently demonstrated that math can be much more ...
(Date:9/15/2014)... Dennis Thompson HealthDay Reporter ... severe respiratory virus believed to have sickened hundreds of ... spread to the Northeast, health officials report. The ... more than a dozen cases of infection with Enterovirus ... asthma. And on Saturday, the Connecticut Department of ...
Breaking Medicine News(10 mins):Health News:Ondine Presenting at the 2014 International Symposium on Photodynamic Therapy and Photodiagnosis 2Health News:Octo Consulting Group Announces it is Opening Two New Offices in Alexandria, Virginia and Atlanta, Georgia to Better Serve Existing and Future Federal Government Clients 2Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3
... CA (June 18, 2010) Leading academic and professional ... online resource that will put the spotlight on research ... http://www.sagepub.com/sageinsight ) links to highly topical articles from across ... SAGE Journals Online. Drawn from both new and archive ...
... ... Pharmaceutical Business , ... York, NY (PRWEB) June 18, 2010 -- LaVoie Group, a leader in life sciences and ... Mr. Pilato will be based in New York, NY and will lead one of ...
... ... issued proceedings against Godstone farm on behalf of Todd and Aaron Furnell, twins exposed to ... ... LLP has today issued proceedings against Godstone farm on behalf of Todd and Aaron Furnell, ...
... 2010: Two separate studies have shown that vitamin D ... diseases, with over half of all patients having below the ... bodies. A further study assessing response to vitamin D ... normalise vitamin D levels in rheumatic disease patients. The results ...
... 2010: The effects of Systemic Lupus Erythematosus (SLE) may ... to results of a new study presented today at ... Against Rheumatism in Rome, Italy. In particular, the study ... Southern European subpopulations. Results from a Europe-wide study, ...
... ... Plumbing service and heating and air conditioning options for homeowners in ... have increased with the arrival of Berkey’s Plumbing, Heating and Air ... expanding its service area into Irving, Haltom City, Euless, Pantego, Hurst, ...
Cached Medicine News:Health News:LaVoie Group Adds Carey Pilato As Vice President Based In New York 2Health News:Vitamin D deficiency confirmed as common across a range of rheumatic conditions 2Health News:Vitamin D deficiency confirmed as common across a range of rheumatic conditions 3Health News:Berkey's Heating and Air Conditioning, Plumbing Service Now in Central DFW Area 2Health News:Berkey's Heating and Air Conditioning, Plumbing Service Now in Central DFW Area 3Health News:Berkey's Heating and Air Conditioning, Plumbing Service Now in Central DFW Area 4
Inquire...
... of electronic refractors. The TRS replaces your standard ... a keypad that is small enough to sit in ... Chart Projector. The TRS is programmable so that at ... moved for you, taking you to your next refraction ...
Uniquely designed, the wheelchair table has dual purposes. Not only does it add a modern look to any office, it is also a heavy-duty table that will support multiple instruments, and/or easily accomm...
... Ideal for satellite clinics or for ... value, the Debut stand is an ... construction and molded composite body offer ... counterbalanced slit-lamp arm--one of two arms ...
Medicine Products: